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Background
A protective vaccine against HIV will likely require elicita-
tion of potent broadly neutralizing antibodies as well as
cellular immunity. mAb 4e10 has the greatest breadth of
the known neutralizing monoclonal antibodies, but
4e10-like antibodies are rarely elicited in natural infec-
tion. The crystal structure of the 4e10 antibody-epitope
complex was solved previously. To develop immunogens
that elicit 4e10-like antibodies, we employed computa-
tional methods to design ''4e10 epitope-scaffolds'' – pro-
tein scaffolds that present and stabilize the 4e10-bound
conformation of the epitope.
Methods
Within the Rosetta protein modeling platform we devel-
oped methods that (1) identified protein scaffolds with
structural similarity to the 4e10 epitope and suitable for
4e10 binding without steric clash; and (2) transplanted
epitope side-chains to scaffolds and optimized the scaf-
fold-antibody interaction. Epitope-scaffolds were
designed automatically and then subjected to human-
guided refinement.
Results
More than twenty epitope-scaffolds were expressed and
purified. Most of the epitope-scaffolds bound to 4e10
with 10- to 1000-fold higher affinity than the cognate
peptide, as assessed by surface plasmon resonance. Crystal
structures of multiple epitope-scaffolds were determined,
both unbound (six structures) and bound (two structures)
to the 4e10 antibody. Multiple bound and unbound
structures revealed near perfect mimicry of the 4e10
epitope conformation. All the epitope-scaffolds tested
blocked broadly-neutralizing activity in serum from an
HIV-1 chronically-infected individual who developed
4E10-like NAbs; one scaffold mutated to kill the epitope
did not block this activity, indicating that the block was
specific to the epitope.
Conclusion
We successfully transferred the 4e10 epitope to non-HIV
protein scaffolds. The scaffolds are useful as candidate
immunogens and as reagents to characterize cross-reactive
neutralizing specificities in HIV+ sera. The immunogen
design methods are general and can be applied to other
epitopes with other conformations.
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